Severity
Moderate
FDA Drug recall · Reported February 2, 2022
CGMP Deviations- Detection of N-Nitrosodimethylamine (NDMA) levels in excess of the Acceptable Daily Intake Limit.
Viona Pharmaceuticals INC recalled Metformin Hydrochloride Extended-Release Tablets, USP 750 mg, 100 count HDPE bottles NDC… - a moderate-severity action.
Metformin Hydrochloride Extended-Release Tablets, USP 750 mg, 100 count HDPE bottles NDC… was recalled by Viona Pharmaceuticals INC in February 2, 2022. Reason: CGMP Deviations- Detection of N-Nitrosodimethylamine (NDMA) levels in excess of the Acceptable Daily Intake L…. Check the official notice for the remedy. Verify recall #D-0392-2022 with the FDA Drug before acting.
The recall
Viona Pharmaceuticals INC issued this moderate-severity FDA Drug recall-CGMP Deviations- Detection of N-Nitrosodimethylamine (NDMA) levels in excess of the Acceptable Daily Intake L….
Sourced from official FDA Drug enforcement records. Verify recall #D-0392-2022 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.
This FDA Drug action (record #D-0392-2022) was formally reported on February 2, 2022, with the manufacturer initiating the action on December 27, 2021. It is classified under Moderate severity (Class II), with a current status of Terminated. Viona Pharmaceuticals INC is listed as the recalling firm, operating out of Cranford, NJ. Federal records list the affected scope as 23,8416/100 count bottles.
The documented reason for this recall is: CGMP Deviations- Detection of N-Nitrosodimethylamine (NDMA) levels in excess of the Acceptable Daily Intake Limit. Distribution data in the federal record shows the product reached: Product was distributed to 17 wholesalers who further distributed the product to 85 locations.. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.
Within the same product category the archive holds 6 closely related recalls, 5 from FDA Drug - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.
Where this recall sits in its category - 14,287 drugs & medications recalls on record
Of 101,704 recalls in the database, 24,878 are high severity, 72,426 moderate, and 4,400 low. This recall is classified moderate severity.
Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.
Severity
Moderate
Affected scope
23,8416/100 count bottles
Related Recalls
6
5 from same agency
Metformin Hydrochloride Extended-Release Tablets, USP 750 mg, 100 count HDPE bottles NDC# 72578-036-01
CGMP Deviations- Detection of N-Nitrosodimethylamine (NDMA) levels in excess of the Acceptable Daily Intake Limit.
| Attribute | Value |
|---|---|
| Agency | U.S. Food and Drug Administration |
| Severity class | Moderate (Class II) |
| Status | Terminated |
| Recall number | D-0392-2022 |
| Date reported | February 2, 2022 |
| Date initiated | December 27, 2021 |
| Recalling firm | Viona Pharmaceuticals INC |
| Firm location | Cranford, NJ |
| Affected scope | 23,8416/100 count bottles |
| Distribution | Product was distributed to 17 wholesalers who further distributed the product to 85 locations. |
Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.
What to do with this recall
Match your product against the recall record, then act on the agency remedy.
This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.
Other recalls in the same product category, useful for spotting patterns across the same defect class or manufacturer.
AbbVie Inc. · 2026-06-03
Llorens Pharmaceuticals International Division, Inc. · 2026-05-27
Safecor Health, LLC · 2026-05-27
IntegraDose Compounding Services LLC · 2026-05-27
Lupin Pharmaceuticals Inc. · 2026-05-27
Compare this recall with PRED MILD, prednisolone acetate ophthalmic suspension, USP,… →
Every figure on PlainRecalls is rendered directly from official FDA, CPSC and NHTSA recall records, no number is typed in by an editor. This recall: FDA Drug, reported February 2, 2022. Severity classes follow each agency's own taxonomy (FDA Class I/II/III; CPSC and NHTSA by hazard type), and related-recall context is computed across the full archive. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of July 2026.